


# New Zealand & international myeloma treatment options & pathways



# First relapse (2nd line treatment)

If transplant eligible, consider second ASCT

First line treatment?

If prior bortezomib\* or carfilzomib treatment

If no prior bortezomib or carfilzomib (or if patient received first-line lenalidomide\*\*)

**Thalidomide-based treatment**

**CTD:** Cyclophosphamide + thalidomide + dexamethasone (dex)  
**TD:** Thalidomide + dex

**or Lenalidomide\*\*/bortezomib/carfilzomib-based treatment**

**Rd:** Lenalidomide + dex

**CRD:** Cyclophosphamide + lenalidomide + dex  
**DVD:** Daratumumab\*\*\* + bortezomib + dex  
**DRD:** Daratumumab + lenalidomide + dex  
**KRd:** Carfilzomib + lenalidomide + dex  
**Kd:** Carfilzomib + dex  
**PomD:** Pomalidomide + dex  
**VD-Pano:** Panobinostat + bortezomib + dex  
**Elo-Rd:** Elotuzumab\*\* + lenalidomide + dex  
**IRd:** Ixazomib\*\* + lenalidomide + dex  
**Vd:** Bortezomib + dex  
**IsaLd:** Isatuximab + lenalidomide + dex

**Thalidomide-based treatment**

**TD:** Thalidomide + dexamethasone (dex)  
**CTD:** Cyclophosphamide + thalidomide + dex

**or Bortezomib-based treatment**

**Vd:** Bortezomib + dex  
**CyBorD:** Cyclophosphamide + bortezomib + dex  
**VCD:** Bortezomib + cyclophosphamide + dex

**DVD:** Daratumumab + bortezomib + dex  
**DRD:** Daratumumab + lenalidomide + dex  
**VD-Pano:** Bortezomib + dex + panobinostat  
**Elo-VD:** Elotuzumab + bortezomib + dex

**or Carfilzomib-based treatment**

**Kd:** Carfilzomib + dex  
**KRd:** Carfilzomib + lenalidomide + dex  
**KCd:** Carfilzomib + cyclophosphamide + dex

# Second (3rd line) or subsequent relapse

Note:

Usual practice in NZ (funded)

Preferred guideline recommended regimens unfunded in NZ

Other funded options available in NZ but less commonly or not used

\* A maximum of 36 doses (up to 9 cycles) of bortezomib is permitted per patient

\*\* Lenalidomide is funded in NZ only at 3rd line, or at 2nd line if patient has a neuropathy

\*\*\* Daratumumab is currently available in NZ on compassionate access

\*\*\*\* B Cell Maturation Antigen

\*\*\*\*\* Bispecific T cell engager

\*\*\*\*\* Antibody drug conjugate

**RD:** Lenalidomide + dex

**PomD:** Pomalidomide + dex  
**DRD:** Daratumumab + lenalidomide + dex  
**DVD:** Daratumumab + bortezomib + dex  
**D:** Daratumumab (single agent)  
**Isa-Ld:** Isatuximab + lenalidomide + dex

**Clinical trials, eg:**  
**Anti-BCMA\*\*\*\* Car-T cell therapy**  
**Anti-BCMA BiTE\*\*\*\*\***  
**Anti-BCMA ADC\*\*\*\*\***